These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 14614026

  • 1. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
    Sabatino MA, Colombo T, Geroni C, Marchini S, Broggini M.
    Clin Cancer Res; 2003 Nov 01; 9(14):5402-8. PubMed ID: 14614026
    [Abstract] [Full Text] [Related]

  • 2. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
    Geroni C, Marchini S, Cozzi P, Galliera E, Ragg E, Colombo T, Battaglia R, Howard M, D'Incalci M, Broggini M.
    Cancer Res; 2002 Apr 15; 62(8):2332-6. PubMed ID: 11956092
    [Abstract] [Full Text] [Related]

  • 3. Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity.
    Lorusso D, Mainenti S, Pietragalla A, Ferrandina G, Foco G, Masciullo V, Scambia G.
    Expert Opin Investig Drugs; 2009 Dec 15; 18(12):1939-46. PubMed ID: 19938904
    [Abstract] [Full Text] [Related]

  • 4. Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.
    Caponigro F, Lorusso D, Fornari G, Barone C, Merlano M, Airoldi M, Schena M, MacArthur R, Weitman S, Jannuzzo MG, Crippa S, Fiorentini F, Petroccione A, Comis S.
    Cancer Chemother Pharmacol; 2010 Jul 15; 66(2):389-94. PubMed ID: 20480279
    [Abstract] [Full Text] [Related]

  • 5. Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin.
    Sabatino MA, Geroni C, Ganzinelli M, Ceruti R, Broggini M.
    Epigenetics; 2013 Jun 15; 8(6):656-65. PubMed ID: 23771052
    [Abstract] [Full Text] [Related]

  • 6. Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
    Beria I, Baraldi PG, Cozzi P, Caldarelli M, Geroni C, Marchini S, Mongelli N, Romagnoli R.
    J Med Chem; 2004 May 06; 47(10):2611-23. PubMed ID: 15115402
    [Abstract] [Full Text] [Related]

  • 7. Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi.
    Mathieu A, Remmelink M, D'Haene N, Penant S, Gaussin JF, Van Ginckel R, Darro F, Kiss R, Salmon I.
    Cancer; 2004 Oct 15; 101(8):1908-18. PubMed ID: 15386340
    [Abstract] [Full Text] [Related]

  • 8. Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment.
    Nagano T, Yasunaga M, Goto K, Kenmotsu H, Koga Y, Kuroda J, Nishimura Y, Sugino T, Nishiwaki Y, Matsumura Y.
    Clin Cancer Res; 2009 Jul 01; 15(13):4348-55. PubMed ID: 19509138
    [Abstract] [Full Text] [Related]

  • 9. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts.
    Kudoh S, Takada M, Masuda N, Nakagawa K, Itoh K, Kusunoki Y, Negoro S, Matsui K, Takifuji N, Morino H.
    Jpn J Cancer Res; 1993 Feb 01; 84(2):203-7. PubMed ID: 8385085
    [Abstract] [Full Text] [Related]

  • 10. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
    Kim DK, Kim HT, Cho YB, Tai JH, Ahn JS, Kim TS, Kim KH, Hong WS.
    Cancer Chemother Pharmacol; 1995 Feb 01; 35(5):441-5. PubMed ID: 7850928
    [Abstract] [Full Text] [Related]

  • 11. A novel synthetic DNA minor groove binder, MS-247: antitumor activity and cytotoxic mechanism.
    Matsuba Y, Edatsugi H, Mita I, Matsunaga A, Nakanishi O.
    Cancer Chemother Pharmacol; 2000 Feb 01; 46(1):1-9. PubMed ID: 10912571
    [Abstract] [Full Text] [Related]

  • 12. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F, Livartowski A, De Cremoux P, Bourgeois Y, Arvelo F, Pouillart P, Poupon MF.
    Clin Cancer Res; 2000 May 01; 6(5):2075-86. PubMed ID: 10815935
    [Abstract] [Full Text] [Related]

  • 13. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M, Benzo A, Irrissuto C, Lopez G, Curatella B, Maggi CA, Manzini S, Crea A, Caroli S, Cubadda F, Binaschi M.
    Cancer Chemother Pharmacol; 2008 Sep 01; 62(4):621-9. PubMed ID: 18038274
    [Abstract] [Full Text] [Related]

  • 14. Brostallicin: a new concept in minor groove DNA binder development.
    Broggini M, Marchini S, Fontana E, Moneta D, Fowst C, Geroni C.
    Anticancer Drugs; 2004 Jan 01; 15(1):1-6. PubMed ID: 15090736
    [Abstract] [Full Text] [Related]

  • 15. Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice.
    Fujimoto S.
    Biol Pharm Bull; 2006 Nov 01; 29(11):2260-6. PubMed ID: 17077525
    [Abstract] [Full Text] [Related]

  • 16. Role of glutathione transferases in the mechanism of brostallicin activation.
    Pezzola S, Antonini G, Geroni C, Beria I, Colombo M, Broggini M, Marchini S, Mongelli N, Leboffe L, MacArthur R, Mozzi AF, Federici G, Caccuri AM.
    Biochemistry; 2010 Jan 12; 49(1):226-35. PubMed ID: 19950984
    [Abstract] [Full Text] [Related]

  • 17. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
    Lai SL, Hwang J, Perng RP, Whang-Peng J.
    Oncol Res; 1995 Jan 12; 7(1):31-8. PubMed ID: 7549042
    [Abstract] [Full Text] [Related]

  • 18. Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells.
    Osaki S, Nakanishi Y, Takayama K, Pei XH, Ueno H, Hara N.
    Cancer Gene Ther; 2000 Feb 12; 7(2):300-7. PubMed ID: 10770640
    [Abstract] [Full Text] [Related]

  • 19. Lentinan enhances sensitivity of mouse colon 26 tumor to cis-diamminedichloroplatinum (II) and decreases glutathione transferase expression.
    Murata T, Hatayama I, Kakizaki I, Satoh K, Sato K, Tsuchida S.
    Jpn J Cancer Res; 1996 Nov 12; 87(11):1171-8. PubMed ID: 9045947
    [Abstract] [Full Text] [Related]

  • 20. In vitro augmentation of antitumor effect in combination with CPT-11 and CDDP for human colorectal cancer.
    Tsunoda T, Tanimura H, Hotta T, Tani M, Iwahashi M, Ishimoto K, Tanaka H, Matsuda K, Yamaue H.
    J Surg Oncol; 2000 Jan 12; 73(1):6-11. PubMed ID: 10649271
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.